Testing NVP-NK4146 for mild cognitive impairment due to Alzheimer's
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new medicine, NVP-NK4146, for people with mild cognitive impairment (MCI) due to Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older
- You have been diagnosed with mild cognitive impairment (MCI) and have a positive amyloid PET scan (a special brain scan showing Alzheimer's-related plaques)
- You do not have dementia (a more severe memory and thinking decline)
- You are not currently being treated for cancer (with some exceptions like long-term recovery or certain skin/prostate cancers your doctor approves)
- You can read, understand, and sign a consent form to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease. It aims to see if the drug is safe and can help slow memory decline.
This study tests whether a medicine called NPC-1 can help people with mild memory or thinking problems or early-stage Alzheimer's. It looks at a blood marker to see if the treatment may slow down the disease.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study tests a new drug called NSC001 for people with mild to moderate Alzheimer's. It checks if the drug is safe and if it might help slow memory decline. You'll need a caregiver who can join you at visits and help track your progress.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.